Heart damage in arterial hypertension. Management of hypertension and contractile dysfunction

Cover Page

Cite item

Full Text

Abstract

The review, based on the data of literature and long-term own studies, shows modern data, concerning the CVS damage in patients with hypertensive disease. The authors demonstrate the clinical and prognostic factors of left ventricle myocardial hypertrophy (LVH) in patients with arterial hypertension (AH) according to the data of echocardiography and electrocardiography. The progression of AH in the elderly is significantly complicated by concomitant diseases: ischaemic heart disease, diabetes mellitus, LVH, etc. The treatment of patients with AH is not associated only with lowering blood pressure but also call for left ventricular mass reduction as a prevention of chronic heart failure. Such drugs as angiotensin-converting enzyme inhibitors, sartans and calcium channel blockers have pathogenetic significance, associated with inhibition of the activity of the renin-angiotensin-aldosterone system. Candesartan is distinguished by the strength of AT1 receptor binding, slow dissociation and rebinding and has a clinically stable long-term antihypertensive effect. Candesartan helps controlling both morning systolic and diastolic BP.

About the authors

M. A Gurevich

M.F.Vladimirskiy Moscow regional research clinical institute

Email: magurevich@mail.ru
д-р мед. наук, проф., каф. терапии ФУВ ГБУЗ МО «МОНИКИ им. М.Ф.Владимирского» 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2

N. A Kuzmenko

M.F.Vladimirskiy Moscow regional research clinical institute

ординатор, каф. терапии ФУВ «МОНИКИ им. М.Ф.Владимирского» 129110, Russian Federation, Moscow, ul. Shchepkina, d. 61/2

References

  1. Brown D.W, Giles W.H, Croft J.B. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140 (6): 848-56.
  2. Levy D, Garrison R.J, Savage D.D et al. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989; 110 (2): 101-7.
  3. Verdecchia P, Porcellati C, Reboldi G et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104 (17): 2039-44.
  4. Danlof B, Devereux R.B, Kieldsen S.E et al, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
  5. Olsen M.H, Wachtell K, Hermann K.L et al. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint - Reduction in Hypertension. Am Heart J 2002; 144 (3): 530-7.
  6. Post W.S, Larson M.G, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994; 90 (1): 179-85.
  7. Appel L.J, Stason W.B. Ambulatory blood pressure monitoring and blood pressure self - measurement in the diagnosis and management of hypertension. Ann Intern Med 1993; 118 (11): 867-82.
  8. Wachtell K, Dahlöf B, Rokkedal J et al. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Am Heart J 2002; 144 (6): 1057-64.
  9. Devereux R.B, Alonso D.R, Lutas E.M et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiology 1986; 57: 450-8.
  10. Kannel W.B, Belanger A.J. Epidemiology of heart failure. Am Heart J 1991; 121 (3 Pt 1): 951-7.
  11. Кушаковский М.С. Гипертоническая болезнь. СПб.: Гиппократ, 1995.
  12. Levy D, Larson M.G, Vasan R.S et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275 (20): 1557-62.
  13. Гогин Е.Е. Гипертоническая болезнь. М., 1997.
  14. European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21 (6): 1011-53.
  15. Sica D.A, Weber M. The Losartan Intervention for Endpoint Reduction (LIFE) trial - have angiotensin - receptor blockers come of age? J Clin Hypertens (Greenwich) 2002; 4 (4): 301-5.
  16. De Luca N, Safar M.E. Efficacy of a very - low - dose perindopril 2 mg/indapamide 0,625 mg on cardiac hypertrophy in hypertensive patients. J Hypertens 2002; 20 (4).
  17. Spratt J, Shiels A, Williams B et al. On behalf of the LVH study group. Effects of candesartan cilexetil on left ventricular and arterial structure and function in hypertensive patients. J Hypertens 2000; 18 (Suppl. 2): S188.
  18. Dahlof B. The PICXEL study benefits of a low dose combination on left ventricular hypertrophy reduction. XIV European Meeting on Hypertension, Paris, 2004.
  19. Mc Clellan K.J, Goa K.L. Candesartan cilexetil. A review of its use in essential hypertension. Drugs 1998; 56: 847-69.
  20. Minatoguchi S, Aoyama Т, Kawai N et a. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press 2013; 22 (l): 29-37.
  21. Cuspidi C, Muiesan M.L, Valagussa L еt al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293-300.
  22. Pfeffer M.A, Swedberg K, Granger C.B et al. For the CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
  23. Easthope S.E, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs 2002; 62: 1253-87.

Copyright (c) 2017 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies